Uppsala University

uu.se

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

453

Active

100

Phase 3

6

Total enrollment

3,475,063

Pipeline matrix

Showing 22 of 22 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Anesthesia Maintenance Agent1
Pivmecillinam1
Standard of Care1
nivolumab or pembrolizumab1
5Fluorouracil1
Irinotecan1
Oxaliplatin1
Spironolactone1
Rituximab1
CAR20(NAP)-T1
Cyclophosphamide1
Fludarabine1
Sequential treatment with rituximab and cladribine1
the ATMP Protrans1
Atezolizumab1
Everolimus1
Cobimetinib1
Niraparib1
AdVince1
ADT + NHT + Docetaxel1
ADT + NHT1
Bortezomib-bendamustine-melphalan1

Next readouts

  • 2024-01-31
  • 2025-03-31
  • 2025-08
  • 2025-12
  • 2026-12
  • 2026-12-10
  • 2026-12-31
  • 2027-12-30
  • 2028-04-01
  • 2028-09

Top conditions

  • Obesity11
  • Chronic Pain10
  • Depression9
  • Sepsis9
  • Acute Kidney Injury8
  • Breast Cancer8
  • Quality of Life7
  • Myocardial Infarction7

Frequently asked questions about Uppsala University

How many clinical trials does Uppsala University have on ClinicalTrials.gov?
Uppsala University is listed as the lead sponsor on 453 clinical trials in ClinicalTrials.gov, 100 of which are currently active (recruiting, enrolling, or ongoing).
How many of Uppsala University's trials are in Phase 3?
6 of Uppsala University's trials are in Phase 3, spread across 22 active drug programs.
What therapeutic areas does Uppsala University focus on?
Uppsala University's most-studied conditions on ClinicalTrials.gov are Obesity, Chronic Pain, Depression, Sepsis, Acute Kidney Injury.
When are Uppsala University's next clinical trial readouts?
Uppsala University has 10 upcoming primary-completion readouts tracked here; the soonest is “A MolEcularly Guided Anti-Cancer Drug Off-Label Trial”, expected around 2024-01-31.